Reduced brain amyloid burden in elderly patients with narcolepsy type 1. Issue 1 (19th December 2018)

• Record Type: Journal Article
• Authors: Gabelle, Audrey; Jaussent, Isabelle; Bouallègue, Fayçal Ben; Lehmann, Sylvain; Lopez, Régis; Barateau, Lucie; Grasselli, Caroline; Pesenti, Carole; de Verbizier, Delphine; Béziat, Séverine; Mariano‐Goulart, Denis; Carlander, Bertrand; Dauvilliers, Yves
• Other Names: Vellas Bruno investigator.; Guyonnet Sophie investigator.; Carrié Isabelle investigator.; Brigitte Lauréane investigator.; Faisant Catherine investigator.; Lala Françoise investigator.; Delrieu Julien investigator.; Villars Hélène investigator.; Combrouze Emeline investigator.; Badufle Carole investigator.; Zueras Audrey investigator.; Andrieu Sandrine investigator.; Cantet Christelle investigator.; Morin Christophe investigator.; Van Kan Gabor Abellan investigator.; Dupuy Charlotte investigator.; Rolland Yves investigator.; Caillaud Céline investigator.; Ousset Pierre‐Jean investigator.; Lala Françoise investigator.; Fougère Bertrand investigator.; Willis Sherry investigator.; Belleville Sylvie investigator.; Gilbert Brigitte investigator.; Fontaine Francine investigator.; Dartigues Jean‐François investigator.; Marcet Isabelle investigator.; Delva Fleur investigator.; Foubert Alexandra investigator.; Cerda Sandrine investigator.; Costes Corinne investigator.; Rouaud Olivier investigator.; Manckoundia Patrick investigator.; Quipourt Valérie investigator.; Marilier Sophie investigator.; Franon Evelyne investigator.; Bories Lawrence investigator.; Pader Marie‐Laure investigator.; Basset Marie‐France investigator.; Lapoujade Bruno investigator.; Faure Valérie investigator.; Tong Michael Li Yung investigator.; Malick‐Loiseau Christine investigator.; Cazaban‐Campistron Evelyne investigator.; Desclaux Françoise investigator.; Blatge Colette investigator.; Dantoine Thierry investigator.; Laubarie‐Mouret Cécile investigator.; Saulnier Isabelle investigator.; Clément Jean‐Pierre investigator.; Picat Marie‐Agnès investigator.; Bernard‐Bourzeix Laurence investigator.; Willebois Stéphanie investigator.; Désormais Iléana investigator.; Cardinaud Noëlle investigator.; Bonnefoy Marc investigator.; Livet Pierre investigator.; Rebaudet Pascale investigator.; Gédéon Claire investigator.; Burdet Catherine investigator.; Terracol Flavien investigator.; Pesce Alain investigator.; Roth Stéphanie investigator.; Chaillou Sylvie investigator.; Louchart Sandrine investigator.; Sudres Kristelle investigator.; Lebrun Nicolas investigator.; Barro‐Belaygues Nadège investigator.; Touchon Jacques investigator.; Bennys Karim investigator.; Gabelle Audrey investigator.; Romano Aurélia investigator.; Touati Lynda investigator.; Marelli Cécilia investigator.; Pays Cécile investigator.; Douillet Patrice investigator.; Robert Philippe investigator.; Le Duff Franck investigator.; Gervais Claire investigator.; Gonfrier Sébastien investigator.; Gasnier Yves investigator.; Bordes Serge investigator.; Begorre Danièle investigator.; Carpuat Christian investigator.; Khales Khaled investigator.; Lefebvre Jean‐François investigator.; El Idrissi Samira Misbah investigator.; Skolil Pierre investigator.; Salles Jean‐Pierre investigator.; Dufouil Carole investigator.; Lehéricy Stéphane investigator.; Chupin Marie investigator.; Mangin Jean‐François investigator.; Bouhayia Ali investigator.; Allard Michèle investigator.; Ricolfi Frédéric investigator.; Dubois Dominique investigator.; Martel Marie Paule Bonceour investigator.; Cotton François investigator.; Bonafé Alain investigator.; Chanalet Stéphane investigator.; Hugon Françoise investigator.; Bonneville Fabrice investigator.; Cognard Christophe investigator.; Chollet François investigator.; Payoux Pierre investigator.; Voisin Thierry investigator.; Delrieu Julien investigator.; Peiffer Sophie investigator.; Hitzel Anne investigator.; Allard Michèle investigator.; Zanca Michel investigator.; Monteil Jacques investigator.; Darcourt Jacques investigator.; Molinier Laurent investigator.; Derumeaux Hélène investigator.; Costa Nadège investigator.; Vincent Christian investigator.; Perret Bertrand investigator.; Vinel Claire investigator.; Olivier‐Abbal Pascale investigator.; Andrieu Sandrine investigator.; Savy Stéphanie investigator.; Cantet Christelle investigator.; Coley Nicola investigator.;
• Is Part Of: Annals of neurology. Volume 85:Issue 1(2019)
• Page Start: 74
• Page End: 83
• Publication Date: 2018-12-19
• Subjects: Neurology -- Periodicals; Pediatric neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; 616.8
• DOI: 10.1002/ana.25373
• Languages: English
• ISSNs: 0364-5134

Abstract

Abstract : Objective: To determine whether brain amyloid burden in elderly patients with narcolepsy type 1 (NT1) is lower than in controls, and to assess in patients with NT1 the relationships between amyloid burden, cerebral spinal fluid (CSF) markers of Alzheimer disease (AD), CSF orexin‐A, and cognitive profile. Methods: Cognitive and 18 F‐florbetapir positron emission tomography (PET) data were compared in patients with NT1 aged ≥ 65 years (n = 23) and in age‐ and sex‐matched controls free of clinical dementia selected from the Alzheimer's Disease Neuroimaging Initiative (ADNI; n = 69) and the Multi‐Domain Intervention Alzheimer's Prevention Trial (MAPT‐18F AV45‐PET; n = 23) cohorts. The standardized uptake values (SUVs) of the cortical retention index for 6 regions of interest were computed and averaged to create a mean SUV ratio normalized to 3 subcortical reference regions (cerebellum, pons, and a composite region). A cortical/cerebellum SUV ratio ≥ 1.17 defined positive PET amyloid. Results: Lower cortical amyloid burden was observed in the NT1 than in the ADNI and MAPT‐AV45 groups (mean cortical/cerebellum SUV ratios = 0.95 ± 0.15, 1.11 ± 0.18 [ p < 0.0001], and 1.14 ± 0.17 [ p = 0.0005], respectively). Similar results were obtained with all subcortical reference regions and for all cortical regions of interest, except cingulum. Only 1 patient with NT1 (4.4%) had positive PET amyloid compared with 27.5% in the ADNI and 30.4% in the MAPT‐AV45 group. In the NT1 group, cortical or regional amyloid load was not associated with CSF orexin‐A, CSF AD biomarkers, or neuropsychological profile. Interpretation: Lower brain amyloid burden, assessed by 18 F‐florbetapir PET, in patients with NT1 suggests delayed appearance of amyloid plaques.ANN NEUROL 2019;85:74–83.